Skip to content
Suven Life Sciences logo

Suven Life Sciences

SUVEN NSE
₹276.10 No trade today
P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹276.10 +83.27 +43.2% 1Y
Start ₹192.83

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
−79.50%
Debt to Equity
0.03
EPS (TTM)
−₹14.44
Book Value
₹24.23
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
11.39
ROE
−81.50%
Dividend Yield
0.00%
EBITDA
−₹271 Cr
52W High
₹403.35
52W Low
₹124.11
Volume
0

Peer Comparison

Healthcare › Healthcare Technology › Healthcare Research, Analytics & Technology

Suven Life Sciences peer comparison
Syngene International
₹417.5076.05₹16,536 Cr3.470.31%7.78%9.99%₹3,600 Cr₹221 Cr
Indegene
₹617.1037.04₹14,947 Cr4.430.37%14.40%18.80%₹3,813 Cr₹401 Cr
Suven Life Sciences (this company)
₹276.10—₹7,549 Cr11.390.00%−81.50%−79.50%₹9 Cr−₹353 Cr
Vimta Labs
₹497.8527.89₹2,195 Cr4.530.41%18.90%25.20%₹419 Cr₹80 Cr
Fabtech Technologies
₹132.309.94₹589 Cr1.340.46%12.50%13.60%₹418 Cr₹49 Cr
Take
₹11.4213.13₹161 Cr5.440.00%16.50%18.50%₹85 Cr₹13 Cr
Median 6 companies₹346.8027.89₹4,872 Cr4.480.34%13.45%16.05%₹419 Cr₹64 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

28 Poor

Data confidence 91/100

Category scores

Quality
3
Poor
Returns, margins, earnings quality 22% weight
Valuation
8
Poor
Cheap vs sector & own history 24% weight
Growth
51
Average
Sales & profit trajectory 9% weight
Financial Health
47
Average
Solvency, leverage, coverage 9% weight
Momentum
52
Average
Trend strength, vol-adjusted 12% weight
Ownership
39
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

7
  • Stock is trading at 12.7 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -4.61%
  • The company has delivered a poor sales growth of -12.0% over past five years.
  • Company has a low return on equity of -65.9% over last 3 years.
  • Debtor days have increased from 63.7 to 77.5 days.
  • Working capital days have increased from 55.6 days to 506 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish856
OscillatorsNeutral252
Moving AveragesStrong Bearish604

Key readings

RSI (14)
44.18
Neutral
MACD (12,26,9)
−14.72
Bullish
SMA (50)
321.07
Bearish
SMA (200)
249.68
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−34.73%
5Y−11.65%
3Y−20.63%
1Y0.00%
TTM+25.00%

Net profit

Net profit growth by window
10YTurned to loss
5YLoss widened by ₹204 Cr
3YLoss widened by ₹158 Cr
1YLoss widened by ₹115 Cr
TTMLoss widened by ₹168 Cr

Operating cash flow

Operating cash flow growth by window
10YTurned negative
5YOutflow widened by ₹204 Cr
3YOutflow widened by ₹184 Cr
1YOutflow widened by ₹145 Cr
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YTiny sales
5YTiny sales
3YTiny sales
1YTiny sales
TTMTiny sales

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹543 Cr
Mar 2018₹625 Cr
Mar 2019₹286 Cr
Mar 2020₹13.00 Cr
Mar 2021₹13.00 Cr
Mar 2022₹12.00 Cr
Mar 2023₹14.00 Cr
Mar 2024₹12.00 Cr
Mar 2025₹7.00 Cr
Mar 2026₹7.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹87.00 Cr
Mar 2018₹124 Cr
Mar 2019−₹24.00 Cr
Mar 2020−₹94.00 Cr
Mar 2021−₹72.00 Cr
Mar 2022−₹122 Cr
Mar 2023−₹118 Cr
Mar 2024−₹105 Cr
Mar 2025−₹161 Cr
Mar 2026−₹276 Cr

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk high

Suven Life Sciences trades at a market cap of ₹8,475 Cr with a negative PE of -31.3x and negative ROE of -79% in the last year, reflecting ongoing losses despite being nearly debt-free. The stock has appreciated 28% over the past year even as sales declined 12% over five years, indicating a sharp disconnect between market pricing and operating fundamentals.

Bull Case 7
  • Company is almost debt-free, providing financial flexibility and low insolvency risk in a capital-intensive healthcare sector
  • Promoter holding increased by 2.79% over the last quarter, signaling insider confidence in the business outlook
  • Stock CAGR of 73% over 3 years suggests sustained market interest and positive sentiment around the company's pipeline potential
  • TTM sales growth has turned positive at 7%, potentially indicating a reversal from the negative 19% 3-year compounded sales decline
  • 10-year stock CAGR of 38% demonstrates long-term wealth creation for shareholders despite operational challenges
  • Near-zero debt gives the company runway to invest in R&D and drug development without servicing obligations eating into cash flows
  • 1-year stock return of 28% outperforms broader market indices, reflecting market re-rating of the business
Bear Case 8
  • Negative PE of -31.3x confirms the company is loss-making at the net income level, with compounded profit declining 67% on a TTM basis
  • 3-year ROE of -65% and last year ROE of -79% indicate severe and worsening destruction of shareholder equity
  • Stock trades at 14.6x book value despite negative returns on equity, suggesting extreme valuation premium relative to asset base
  • Compounded sales growth is negative at -12% over 5 years and -35% over 10 years, reflecting a structurally shrinking revenue base
  • Working capital days have ballooned from 2,939 to 9,156 days, indicating severely inefficient capital utilization and potential cash conversion issues
  • Debtor days increased from 63.7 to 77.5 days, suggesting deterioration in collection efficiency and potential customer concentration risk
  • Zero dividend yield means shareholders receive no income return while bearing significant operational risk from ongoing losses
  • Low interest coverage ratio despite being nearly debt-free suggests operating earnings are insufficient to cover even minimal financial obligations

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: Suven Life Sciences is firing on multiple cylinders in its clinical pipeline with positive Phase-2b data for Ropanicant in depression, Phase-2 advancement of SUVN-I6107, and upcoming Samelisant presentations. No headwinds are visible in recent news flow. The key risk remains typical biotech execution risk around Phase-3 trial outcomes and partnering timelines, but the near-term trend is clearly positive with pipeline catalysts stacking up through 2026.

Positives 4
  • Ropanicant Phase-2b hits primary endpoint Jun 17

    Phase-2b trial for Major Depressive Disorder showed statistically significant improvement on primary endpoint with no serious safety signals. Company plans to initiate global Phase-3 studies.

  • SUVN-I6107 advances to Phase-2 Jun 16

    Phase-1 completed successfully showing favorable safety and CNS activity. Drug now moves into Phase-2 clinical development.

  • Samelisant data at SLEEP-2026 Jun 12

    Three posters to be presented at SLEEP-2026 in Baltimore, including Phase-2 results and Phase-3 study design for Samelisant.

Neutral 1
  • Promoters hold unpledged shares in FY26 Jun 17

    No promoter shares were pledged during FY26 as disclosed under SEBI regulations, indicating clean promoter holding structure.

Quarterly Results

₹ Cr
SUVEN quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
4
3
2
2
1
3
2
1
2
1
3
2
4
Expenses
32
27
49
33
32
55
41
45
53
81
106
52
136
Operating Profit
−28
−24
−46
−30
−31
−52
−39
−44
−51
−80
−103
−51
−132
OPM %
−737%
−768%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Other Income
6
13
6
4
4
4
2
1
1
4
3
7
8
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
2
2
2
2
1
1
2
1
1
1
1
2
2
PBT
−24
−13
−42
−28
−28
−50
−39
−44
−52
−77
−102
−46
−128
Tax %
0%
0%
0%
−4%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
−24
−13
−42
−27
−28
−50
−39
−44
−52
−77
−102
−46
−128
EPS (₹)
−1.1
−0.58
−1.91
−1.22
−1.29
−2.28
−1.79
−2.01
−2.36
−3.4
−4.48
−1.73
−4.83

Profit & Loss

₹ Cr
SUVEN profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
521
499
543
625
286
13
13
12
14
12
7
7
9
Expenses
361
398
414
427
300
128
93
134
139
140
172
291
375
Operating Profit
159
102
129
198
−14
−116
−80
−122
−126
−128
−166
−284
−366
OPM %
31%
20%
24%
32%
−5%
−917%
−593%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
−929%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Other Income
9
19
21
23
27
14
8
5
14
29
11
14
21
Interest
5
6
6
5
2
1
1
1
0
0
0
0
1
Depreciation
12
18
21
21
11
4
4
4
7
6
6
6
6
PBT
152
98
123
196
0
−106
−77
−122
−118
−106
−161
−276
−352
Tax %
28%
26%
29%
37%
15038%
−11%
−7%
0%
0%
−1%
0%
0%
—
Net Profit
109
72
87
124
−24
−94
−72
−122
−118
−105
−161
−276
−352
EPS (₹)
5.7
3.76
4.57
6.48
−1.25
−4.94
−3.78
−5.59
−5.42
−4.82
−7.37
−10.48
−14.44
Div. Payout %
7%
35%
15%
15%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
SUVEN balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
15
22
22
22
26
Reserves
547
583
654
755
226
131
95
82
354
248
88
565
Borrowings
109
83
71
34
3
6
5
3
2
1
0
17
Other Liabilities
105
74
78
118
62
33
16
9
12
14
25
16
Total Liabilities
773
751
816
919
303
182
128
108
389
285
135
624
Fixed Assets
172
305
306
308
22
25
21
38
37
28
60
73
CWIP
107
7
10
25
0
0
5
4
0
0
0
4
Investments
0
0
301
279
223
0
0
45
46
76
22
181
Other Assets
494
439
199
308
58
157
103
22
305
181
53
367
Total Assets
773
751
816
919
303
182
128
108
389
285
135
624

Cash Flow

₹ Cr
SUVEN cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
143
68
109
70
−53
−135
−96
−128
−116
−115
−155
−300
Investing
−110
−39
−311
−1
30
146
56
−22
−248
94
155
−462
Financing
179
−68
−30
−52
5
3
35
146
396
−1
−1
757
Net Cash Flow
212
−39
−232
17
−18
14
−5
−4
32
−22
−1
−5
Free Cash Flow
25
10
79
28
−92
−137
−102
−147
−119
−113
−193
−305
CFO/EBITDA
113
93
111
57
262
114
119
104
91
95
93
106

Ratios

SUVEN financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28
39
31
36
3
66
48
40
22
40
73
78
Inventory Days
165
183
222
329
0
—
—
—
—
—
—
—
Days Payable
89
78
91
134
—
—
—
—
—
—
—
—
Cash Conversion Cycle
105
144
162
231
3
66
48
40
22
40
73
78
Working Capital Days
49
55
42
82
23
704
1,084
234
265
101
−440
506
ROCE %
—
13%
15%
24%
−4%
−54%
−58%
−118%
−53%
−36%
−87%
−80%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Suven Life Sciences insights

64 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 65.47%
  • Public 24.85%
  • Others 7.05%
  • DIIs 2.17%
  • FIIs 0.46%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Suven Life Sciences

What does Suven Life Sciences Ltd do?
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.
Where is Suven Life Sciences Ltd (SUVEN) listed?
Suven Life Sciences Ltd trades as SUVEN on the NSE and under code 530239 on the BSE.
Which sector does Suven Life Sciences Ltd belong to?
Suven Life Sciences Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the 52-week high and low of Suven Life Sciences Ltd?
Over the last 52 weeks Suven Life Sciences Ltd has traded between ₹124.11 and ₹403.35 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Suven Life Sciences Ltd?
Suven Life Sciences Ltd reported a return on equity of -81.50%. Its debt-to-equity ratio is 0.03.

Company Information

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.

Website suven.com
CEO Mr. Venkateswarlu Jasti M.Pharm. M.S.
Employees 138
Listed 23 Oct 2003
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUVEN.md for Suven Life Sciences Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month